31. Mai 2023 | 28:55 min.
Artikel-Serie – 4 von 5 Insights
The EC pharma and patent package – what’s important to know from a patent law perspective?
End of April, the European Commission presented its draft for a comprehensive reform of pharmaceutical legislation as well as draft regulations that provide for a unitary SPC, a centralised application for “classic” SPCs and an EU wide compulsory license.
It is planning the biggest pharmaceutical reform in 20 years. In particular, the SPC system is to be simplified and streamlined, an EU wide compulsory licensing system shall be implemented in order to tackle future crises and emergencies and questions regarding the possibility to rely on Bolar exemptions are to be clarified.
But what can companies in the sector expect and what issues should they be aware of? Get an overview here.
Download our presentation "The EC pharma and patent package"
Download our presentation: The EC pharma and patent package
The European Commission's pharmaceutical reform package
core objectives and planned changes at a glance
Read the entire articleIn dieser Serie
Das Pharma-Paket der Europäischen Kommission: Kernziele und geplante Änderungen auf einen Blick
10. Mai 2023
Das Pharma-Paket der Europäischen Kommission: Kernziele und geplante Änderungen
25. Mai 2023
Das neue Pharma-Paket der EU-Kommission: Geänderter Rechtsrahmen für Unterlagenschutz, Vermarktungsschutz und Marktexklusivität
31. Mai 2023
The EC pharma and patent package – what’s important to know from a patent law perspective?
31. Mai 2023
Das Pharma-Paket: Die geplanten Änderungen im Zulassungsverfahren und in der Arzneimittelwerbung
31. Mai 2023
Related Insights
Claiming the clock: Mastering patent limitation periods and their impact on contract design| Life Sciences Quarterly #2
IP: Licensing and insolvency
von mehreren Autoren
